Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
NCT ID: NCT04986137
Last Updated: 2022-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-09-04
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The diagnostic performance of Fractional Excretion of Urea (FEUrea) for the differential diagnosis of acute kidney injury in patients with cirrhosis and ascites presenting to a tertiary care hospital.
* The ability of Fractional Excretion of Urea to distinguish between
1. structural group of acute kidney injury (acute tubular necrosis) versus functional group of acute kidney injury (prerenal azotemia and hepatorenal syndrome), and
2. types of functional group (prerenal azotemia versus hepatorenal syndrome type 1).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis
NCT03675633
Acute Kidney Injury in Patients With Liver Cirrhosis
NCT06343389
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
NCT02049125
Acute Kidney Injury as a Risk Factor for Myocardial Injury and Ventricular Dysfunction
NCT04768751
Acute Kidney Injury in Neonates at NICU in Assiut University Children Hospital Descriptive Study
NCT03528837
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are two types of AKI in cirrhosis: functional and structural. The functional group is divided into the volume responsive prerenal azotemia (PRA) that results from decreases in intravascular volume (e.g., aggressive diuretic treatment, diarrhea) and volume-unresponsive state or called hepatorenal syndrome (HRS). AKI that is unresponsive to albumin infusion and withdrawal of diuretics in the absence of identifiable causes. The structural group includes acute tubular necrosis (ATN) that results from intrinsic damage and other renal parenchymal disorders.
Urea is filtered in the glomerulus and then largely reabsorbed in the proximal tubule and also in the distal tubule. The reabsorption of urea is increased by vasopressin and the renin-angiotensin-aldosterone system. The fractional excretion of urea under conditions of decreased renal perfusion and increased vasopressin and renin-angiotensin-aldosterone system (RAAS), such as that seen in cirrhosis with PRA or HRS type 1, should therefore decrease. Conversely, renal tubular injury should impair reabsorption and increase its fractional excretion. Since urea absorption is largely modulated in the proximal tubules, it is not affected by diuretics acting more distally. Recently it is therefore hypothesized that the fractional excretion of urea (FEUrea) could serve as a clinical aid in making an early distinction between ATN versus PRA and HRS type 1 in patients with cirrhosis and ascites presenting with AKI. The current study was designed to test this hypothesis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Acute kidney injury due to acute tubular necrosis
No interventions assigned to this group
Group 2
Acute kidney injury due to prerenal azotemia
No interventions assigned to this group
Group 3
Acute kidney injury due to hepatorenal syndrome type 1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decompensated liver cirrhosis (Child-Pugh classification B or more) of any etiology diagnosed by clinical parameters involving laboratory tests, endoscopic or radiologic evidence of cirrhosis, history of decompensation (hepatic encephalopathy, ascites, variceal bleeding, jaundice), and liver biopsy if available.
* Use of either loop diuretics and/or distal diuretics (ex; spironolactone and eplerenone) until the time of admission.
* Availability of a baseline serum creatinine as defined by the International Club Ascites.
Exclusion Criteria
* Advanced chronic kidney disease defined as serum creatinine greater than 4 mg/dL
* Patients on acute or chronic renal replacement therapy
* Patients with hepatocellular carcinoma.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mahmoud Khalaf Mahmoud
Assistant lecturer of Internal Medicine. Faculty of Medicine, Aswan University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eman A Sabet, Professor
Role: PRINCIPAL_INVESTIGATOR
Suhag University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan University Hospitals
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
[email protected]
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-21-07-25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.